As of 2025-08-02, the Intrinsic Value of InterCure Ltd (INCR.TA) is (1,284.79) ILS. This INCR.TA valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 499.10 ILS, the upside of InterCure Ltd is -357.40%.
The range of the Intrinsic Value is (14,895.15) - (655.72) ILS
Based on its market price of 499.10 ILS and our intrinsic valuation, InterCure Ltd (INCR.TA) is overvalued by 357.40%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (14,895.15) - (655.72) | (1,284.79) | -357.4% |
| DCF (Growth 10y) | (850.43) - (39,563.86) | (2,120.24) | -524.8% |
| DCF (EBITDA 5y) | (617.99) - (1,962.67) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (759.34) - (2,998.94) | (1,234.50) | -123450.0% |
| Fair Value | -2,530.18 - -2,530.18 | -2,530.18 | -606.95% |
| P/E | (1,396.66) - (1,427.02) | (1,366.30) | -373.8% |
| EV/EBITDA | (383.59) - (426.01) | (396.41) | -179.4% |
| EPV | (175.02) - (270.83) | (222.93) | -144.7% |
| DDM - Stable | (734.40) - (2,503.79) | (1,619.10) | -424.4% |
| DDM - Multi | (2,454.57) - (6,883.25) | (3,664.83) | -834.3% |
| Market Cap (mil) | 280.41 |
| Beta | 0.64 |
| Outstanding shares (mil) | 0.56 |
| Enterprise Value (mil) | 370.31 |
| Market risk premium | 6.13% |
| Cost of Equity | 10.64% |
| Cost of Debt | 62.10% |
| WACC | 32.23% |